Antiangiogenic Activity of Alofanib, an Allosteric Inhibitor of Fibroblast Growth Factor Receptor 2
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605536880 | ||
| 003 | CHVBK | ||
| 005 | 20210128100854.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20151101xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10517-015-3104-5 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10517-015-3104-5 | ||
| 245 | 0 | 0 | |a Antiangiogenic Activity of Alofanib, an Allosteric Inhibitor of Fibroblast Growth Factor Receptor 2 |h [Elektronische Daten] |c [D. Khochenkov, E. Solomko, N. Peretolchina, O. Ryabaya, E. Stepanova] |
| 520 | 3 | |a Alofanib is a potential allosteric inhibitor of FGFR2 used in oncology. The inhibitor blocks the extracellular part of the receptor and prevents its binding with the ligand. Alofanib suppressed proliferation of endothelial cells, their migration activity, and ability to form vessellike structures in vitro and significantly decreased the number of microvessels in Matrigel implant and in ovarian cancer (SKOV-3) xenograft in vivo. The results indicate that Alofanib can inhibit angiogenesis. | |
| 540 | |a Springer Science+Business Media New York, 2015 | ||
| 690 | 7 | |a alofanib |2 nationallicence | |
| 690 | 7 | |a allosteric inhibitor of FGFR2 |2 nationallicence | |
| 690 | 7 | |a tumor angiogenesis |2 nationallicence | |
| 690 | 7 | |a endothelial cells |2 nationallicence | |
| 700 | 1 | |a Khochenkov |D D. |u N. N. Blokhin Russian Cancer Research Center, Moscow, Russia |4 aut | |
| 700 | 1 | |a Solomko |D E. |u N. N. Blokhin Russian Cancer Research Center, Moscow, Russia |4 aut | |
| 700 | 1 | |a Peretolchina |D N. |u N. N. Blokhin Russian Cancer Research Center, Moscow, Russia |4 aut | |
| 700 | 1 | |a Ryabaya |D O. |u N. N. Blokhin Russian Cancer Research Center, Moscow, Russia |4 aut | |
| 700 | 1 | |a Stepanova |D E. |u N. N. Blokhin Russian Cancer Research Center, Moscow, Russia |4 aut | |
| 773 | 0 | |t Bulletin of Experimental Biology and Medicine |d Springer US; http://www.springer-ny.com |g 160/1(2015-11-01), 84-87 |x 0007-4888 |q 160:1<84 |1 2015 |2 160 |o 10517 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10517-015-3104-5 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10517-015-3104-5 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Khochenkov |D D. |u N. N. Blokhin Russian Cancer Research Center, Moscow, Russia |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Solomko |D E. |u N. N. Blokhin Russian Cancer Research Center, Moscow, Russia |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Peretolchina |D N. |u N. N. Blokhin Russian Cancer Research Center, Moscow, Russia |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Ryabaya |D O. |u N. N. Blokhin Russian Cancer Research Center, Moscow, Russia |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Stepanova |D E. |u N. N. Blokhin Russian Cancer Research Center, Moscow, Russia |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Bulletin of Experimental Biology and Medicine |d Springer US; http://www.springer-ny.com |g 160/1(2015-11-01), 84-87 |x 0007-4888 |q 160:1<84 |1 2015 |2 160 |o 10517 | ||